Notable
EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Primary endpoint(s) modified
Also in this update: Trial completed; Final enrollment: 7 participants (planned 15)
Elixiron Immunotherapeutics Inc.Phase 2 NCT06745583 Registry history of NCT06745583 on ClinicalTrials.gov (opens the registry)